- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Naim Alkhouri, MD
Naim Alkhouri, MD, FAASLD, DABOM, is the chief of transplant hepatology and director of the Steatotic Liver Program at Arizona Liver Health.
Articles
Semaglutide Shows Promise for MASH Resolution, Severe Fibrosis: Naim Alkhouri, MD
May 9th 2025Naim Alkhouri, MD, spoke to the potential for glucagon-like peptide-1 (GLP-1) receptor agonists to transform the treatment landscape for patients with metabolic dysfunction-associated steatohepatitis (MASH) and severe fibrosis.
Early Identification of MASLD/MASH Saves Lives: Naim Alkhouri, MD
May 6th 2025Lacking awareness of metabolic dysfunction-associated steatohepatitis (MASH) constitutes a critical barrier for enhancing patient care, said Naim Alkhouri, MD. Awareness efforts can not only increase patient access, but also improve the overall wellbeing, experience, and outcomes for this population.
New Hope and Persistent Challenges for MASH Treatment: Naim Alkhouri, MD
April 17th 2025Recent advances have marked a turning point for the treatment noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), with more therapies on the horizon to hopefully better address patients' cirrhosis, explained Naim Alkhouri, MD.
